局部消融治疗联合帕博利珠单抗治疗同时性寡转移非小细胞肺癌:一项递归分区分析
该回顾性研究纳入258例同时性寡转移非小细胞肺癌患者,78例接受局部消融治疗(LAT)联合帕博利珠单抗,180例仅接受帕博利珠单抗。LAT与显著改善的无进展生存期(PFS)和总生存期(OS)独立相关;基于转移灶数量、体能状态和PD-L1表达构建的递归分区分析(RPA)模型将患者分为3个风险组,LAT在低危和中危组中显著改善PFS和OS,在高危组中未见差异。
要点
- LAT联合帕博利珠单抗与仅用帕博利珠单抗相比,全队列PFS(HR 0.64,P=0.015)和OS(HR 0.61,P=0.020)显著改善。
- 倾向性评分匹配队列中,LAT组中位PFS 19.9个月 vs 非LAT组9.6个月(P=0.003),中位OS 42.2个月 vs 20.5个月(P=0.045)。
- RPA模型基于转移灶数量、体能状态和PD-L1表达将患者分为3个风险组,LAT在低危和中危组显著改善PFS和OS,高危组无差异。
核心结论
- 在经选择的同步寡转移非小细胞肺癌患者中,LAT联合帕博利珠单抗与仅用帕博利珠单抗相比,与更高的PFS和OS相关。
- RPA模型可作为识别适合接受LAT患者的临床工具。
研究设计与样本
- 回顾性研究,纳入2017年1月至2022年12月间诊断为同步寡转移非小细胞肺癌(转移灶≤5个且受累器官≤3个)并接受一线帕博利珠单抗治疗的患者。
- 共纳入258例患者,其中78例接受LAT(手术或放疗覆盖所有病灶)联合帕博利珠单抗,180例仅接受帕博利珠单抗。
- 使用PFS的预后因素构建递归分区分析(RPA)模型。
主要发现
- 中位随访时间15.5个月(范围3.0-71.2个月)。
- 全队列中,LAT与显著改善的PFS独立相关(HR 0.64;P=0.015),与显著改善的OS独立相关(HR 0.61;P=0.020)。
- 倾向性评分匹配队列(每组74例)中,LAT组和非LAT组的中位PFS分别为19.9个月和9.6个月(P=0.003),中位OS分别为42.2个月和20.5个月(P=0.045)。
- RPA模型纳入转移灶数量、体能状态和程序性死亡配体1表达水平,将患者分为3个具有不同PFS的风险组。
- LAT在低危和中危组中显著改善PFS和OS,但在高危组中未观察到差异。
关键数值与推荐
- 同步寡转移非小细胞肺癌定义为转移灶≤5个且受累器官≤3个。
- RPA模型基于转移灶数量、体能状态和PD-L1表达水平将患者分为3个风险组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the efficacy of local ablative therapy (LAT) combined with pembrolizumab in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) and to identify patients who would most benefit from LAT. METHODS AND MATERIALS: We retrospectively identified patients who received diagnosis of synchronous oligometastatic NSCLC (≤5 metastatic lesions and ≤3 organs involved) and were treated with first-line pembrolizumab between January 2017 and December 2022. Patients who underwent LAT, including surgery or radiation therapy at all disease sites, were compared with those who did not undergo LAT. A recursive partitioning analysis (RPA) model was developed using prognostic factors for progression-free survival (PFS). RESULTS: Among the 258 patients included, 78 received LAT with pembrolizumab, and 180 received pembrolizumab alone. The median follow-up duration was 15.5 months (range, 3.0-71.2 months). In the entire cohort, LAT was independently associated with significantly improved PFS (hazard ratio [HR], 0.64; P = .015) and overall survival (OS) (HR, 0.61; P = .020). In the propensity score-matched cohort (N = 74 in each group), the median PFS was 19.9 months and 9.6 months, respectively (P = .003), and the median OS was 42.2 months and 20.5 months, respectively (P = .045), for the LAT and non-LAT groups. Based on the RPA model, incorporating the number of metastatic lesions, performance status, and programmed cell death-ligand 1 expression level, patients were stratified into 3 risk groups with distinct PFS. LAT significantly improved PFS and OS in the low- and intermediate-risk groups; however, no difference was observed in the high-risk group. LAT was more effective as a consolidative treatment after pembrolizumab initiation than as an upfront therapy. CONCLUSIONS: LAT combined with pembrolizumab was associated with higher PFS and OS compared with pembrolizumab alone in selected patients with synchronous oligometastatic NSCLC. The RPA model could serve as a valuable clinical tool for identifying appropriate patients for LAT.
引用
- Lee HI, Choi EK, Kim SS, et al. Local Ablative Therapy Combined With Pembrolizumab in Patients With Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis. Int J Radiat Oncol Biol Phys. 2024. PMID: 38797499. doi:10.1016/j.ijrobp.2024.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。